EFFICACY AND SAFETY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS STRATIFIED BY AGE: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION AND SELECTIONLTE STUDIES

被引:0
|
作者
Schreiber, Stefan
Loftus, Edward V.
Maaser, Christian
Danese, Silvio
Rudolph, Christine
Jongen, Rob
de Haas, Angela
Oortwijn, Alessandra
Vermeire, Severine
机构
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Su1565
引用
收藏
页码:S633 / S634
页数:2
相关论文
共 50 条
  • [21] Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
    Vermeire, S.
    Feagan, B.
    Peyrin-Biroulet, L.
    Oortwijn, A.
    Faes, M.
    de Haas, A.
    Rogler, G.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I473 - I474
  • [22] RE-TREATMENT WITH FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS FOLLOWING TREATMENT INTERRUPTION: ANALYSIS OF THE SELECTION AND SELECTIONLTE STUDIES
    Vermeire, Severine
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Oortwijn, Alessandra
    Faes, Margaux
    de Haas, Angela
    Rogler, Gerhard
    GASTROENTEROLOGY, 2022, 162 (07) : S971 - S971
  • [23] Characteristics of filgotinib-treated patients with Ulcerative Colitis who achieve sustained corticosteroid-free remission: Post hoc analysis of the phase 2b/3 SELECTION study
    Kobayashi, T.
    Dignass, A.
    Roblin, X.
    Fujitani, Y.
    Oortwijn, A.
    Jamoul, C.
    Hibi, T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 459 - 460
  • [24] Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial (vol 17, pg 1207, 2023)
    Dotan, Iris
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (02): : 335 - 335
  • [25] Safety of Filgotinib in Crohn's Disease Compared with Ulcerative Colitis: Data from the Phase 3 DIVERSITY1 and Phase 2b/3 SELECTION Studies
    Schreiber, Stefan
    Vermeire, Severine
    Rubin, David T.
    Danese, Silvio
    Mehta, Rajiv
    Roblin, Xavier
    Kwon, Paul
    van Hoek, Paul
    Masior, Tomasz
    Barron, Rahul
    Le Brun, Franck-Olivier
    Watanabe, Mamoru
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S682 - S682
  • [26] Filgotinib induction-study baseline characteristics of patients with ulcerative colitis who achieve sustained corticosteroid-free remission: post hoc analysis of the phase 2b/3 SELECTION study
    Kobayashi, Taku
    Dignass, Axel
    Roblin, Xavier
    Takatori, Yoshie
    Kaise, Toshihiko
    Oortwijn, Alessandra
    Jamoul, Corinne
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2024,
  • [27] Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
    Feagan, B. G.
    Matsuoka, K.
    Rogler, G.
    Faes, M.
    Oortwijn, A.
    de Haas, A.
    Rudolph, C.
    Patel, H.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I456 - I457
  • [28] Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE (vol 58, pg 874, 2023)
    Schreiber, S.
    Rogler, G.
    Watanabe, M.
    Vermeire, S.
    Maaser, C.
    Danese, S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 302 - 302
  • [29] Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
    Danese, Silvio
    Ferrante, Marc
    Feagan, Brian G.
    Peyrin-Biroulet, Laurent
    Hibi, Toshifumi
    Sandborn, William J.
    Schreiber, Stefan
    Ritter, Timothy
    Loftus, Edward V.
    Rogler, Gerhard
    Oortwijn, Alessandra
    Yun, Chohee
    Le Brun, Franck-Olivier
    Dinoso, Jason
    Hsieh, Jeremy
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (01): : 138 - 147
  • [30] Efficacy and safety outcomes of long-term treatment with filgotinib 200 mg among patients with Ulcerative Colitis: An interim analysis of SELECTIONLTE
    Matsuoka, K.
    Rogler, G.
    Faes, M.
    Oortwijn, A.
    de Haas, A.
    Rudolph, C.
    Patel, H.
    Peyrin-Biroulet, L.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I456 - I457